The first selective MAGL inhibitor (JZL184) raised brain 2-AG levels eightfold in mice and produced pain relief, hypothermia, and reduced movement through CB1 receptors, demonstrating that 2-AG is a key endogenous modulator of cannabinoid-associated behaviors.
Read this if you want to understand the role of 2-AG, one of the body's main cannabinoid-like molecules.
Brain 2-AG increased 8-fold with no change in anandamide
What the researchers found
Researchers developed JZL184, the first potent and selective inhibitor of MAGL, the enzyme that breaks down the endocannabinoid 2-AG.
When administered to mice, JZL184 raised brain 2-AG levels eightfold without altering anandamide levels, confirming that MAGL is the primary enzyme responsible for 2-AG degradation in the brain.
Mice treated with JZL184 exhibited analgesia, hypothermia, and reduced movement, all classic cannabinoid effects that were blocked by a CB1 receptor antagonist, confirming they were mediated through the cannabinoid system.
These findings established that 2-AG endogenously modulates several behavioral processes traditionally associated with cannabis pharmacology.
Why it matters
This was the first demonstration that selectively raising 2-AG levels produces a broad array of cannabinoid-like effects, establishing 2-AG as a major player in endocannabinoid signaling and opening new therapeutic possibilities.
The numbers in context
Brain 2-AG increased 8-fold. Anandamide levels were not altered. JZL184 produced analgesia, hypothermia, and hypomotility. All behavioral effects were CB1-dependent.
How the study worked
Preclinical pharmacological study. JZL184 was characterized biochemically for selectivity and potency against MAGL. Brain endocannabinoid levels were measured after administration. Behavioral effects (analgesia, hypothermia, hypomotility) were assessed and confirmed as CB1-dependent using a selective antagonist.
What this study cannot tell us
Animal study using acute dosing only. Long-term effects and potential tolerance development were not examined. The relationship between mouse behavioral effects and human therapeutic outcomes is uncertain.
How to read the evidence
Landmark preclinical study published in Nature Chemical Biology with rigorous biochemical and behavioral characterization. Limited to animal models.
When this study was published
Published in 2009. This was a foundational study that enabled much subsequent endocannabinoid research. MAGL inhibitors have since been developed for clinical testing.
The bigger picture
Before this study, the relative contributions of anandamide versus 2-AG to cannabinoid-associated behaviors were unclear. By selectively raising 2-AG, researchers showed it modulates core cannabinoid behaviors, fundamentally advancing understanding of endocannabinoid pharmacology.
Questions still open
- Does tolerance develop to the effects of chronic MAGL inhibition? Could MAGL inhibitors serve as alternatives to cannabis for pain management? What are the side effect profiles compared to direct CB1 agonists?
Common questions
What is 2-AG?
Could this lead to new medications?
Read the original research
Selective blockade of 2-arachidonoylglycerol hydrolysis produces cannabinoid behavioral effects.
Nature chemical biology, 5(1), 37-44
Citation
Long, Jonathan Z; Li, Weiwei; Booker, Lamont; Burston, James J; Kinsey, Steven G; Schlosburg, Joel E; Pavón, Franciso J; Serrano, Antonia M; Selley, Dana E; Parsons, Loren H; Lichtman, Aron H; Cravatt, Benjamin F. (2009). Selective blockade of 2-arachidonoylglycerol hydrolysis produces cannabinoid behavioral effects.. Nature chemical biology, 5(1), 37-44. https://doi.org/10.1038/nchembio.129
Explore the wider topic
- How THC Affects Your Amygdala: The Brain's Threat Detector and Cannabis
- The Anandamide Connection: Your Body's Natural Bliss Molecule
- How Long for Cannabinoid Receptors to Return to Normal
- Cannabis and the Developing Brain: What Every Teenager (and Parent) Should Know
- Why Can't I Enjoy Anything Without Weed? The Science Behind It
- Dopamine Recovery After Quitting Weed: What the Science Says
- The Endocannabinoid System Explained Simply: What It Does and Why It Matters
- Your Endocannabinoid System Explained: Why Withdrawal Happens
- Your Nervous System After Quitting Weed: Fight or Flight
- Using Weed Under 18: What It Does to Your Developing Brain
- What THC Does to Your Brain: Why Withdrawal Happens
- THC and Your Prefrontal Cortex: What Cannabis Does to Your Decision-Making Brain
- Weed, Cortisol, and Stress: What Cannabis Does to Your Stress Hormones
- Weed and Memory: What the Science Says About THC and Your Hippocampus
- Weed and Motivation: Is Amotivational Syndrome Real?
- Weed and Your Nervous System: What THC Actually Does to Your Brain and Body
- How Weed Rewires Your Reward System (And How to Reset It)